Acceptance and Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell Transplantation
Conditions: Systemic Sclerosis; SARS-CoV 2 Vaccination Intervention: Sponsor: Assistance Publique - Hôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
A Study on the Safety and Immune Response of a Booster Dose of Investigational COVID-19 mRNA Vaccines in Healthy Adults
Condition: SARS-CoV-2 Interventions: Biological: CV0701 Bivalent High dose; Biological: CV0701 Bivalent Medium dose; Biological: CV0701 Bivalent Low dose; Biological: CV0601 Monovalent High dose; Biological: Control vaccine Sponsors: GlaxoSmithKline; CureVac Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
Acceptance and Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell Transplantation
Conditions: Systemic Sclerosis; SARS-CoV 2 Vaccination Intervention: Sponsor: Assistance Publique - Hôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
A Study on the Safety and Immune Response of a Booster Dose of Investigational COVID-19 mRNA Vaccines in Healthy Adults
Condition: SARS-CoV-2 Interventions: Biological: CV0701 Bivalent High dose; Biological: CV0701 Bivalent Medium dose; Biological: CV0701 Bivalent Low dose; Biological: CV0601 Monovalent High dose; Biological: Control vaccine Sponsors: GlaxoSmithKline; CureVac Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
Acceptance and Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell Transplantation
Conditions: Systemic Sclerosis; SARS-CoV 2 Vaccination Intervention: Sponsor: Assistance Publique - Hôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
A Study on the Safety and Immune Response of a Booster Dose of Investigational COVID-19 mRNA Vaccines in Healthy Adults
Condition: SARS-CoV-2 Interventions: Biological: CV0701 Bivalent High dose; Biological: CV0701 Bivalent Medium dose; Biological: CV0701 Bivalent Low dose; Biological: CV0601 Monovalent High dose; Biological: Control vaccine Sponsors: GlaxoSmithKline; CureVac Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
Acceptance and Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell Transplantation
Conditions: Systemic Sclerosis; SARS-CoV 2 Vaccination Intervention: Sponsor: Assistance Publique - Hôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
A Study on the Safety and Immune Response of a Booster Dose of Investigational COVID-19 mRNA Vaccines in Healthy Adults
Condition: SARS-CoV-2 Interventions: Biological: CV0701 Bivalent High dose; Biological: CV0701 Bivalent Medium dose; Biological: CV0701 Bivalent Low dose; Biological: CV0601 Monovalent High dose; Biological: Control vaccine Sponsors: GlaxoSmithKline; CureVac Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
Acceptance and Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell Transplantation
Conditions: Systemic Sclerosis; SARS-CoV 2 Vaccination Intervention: Sponsor: Assistance Publique - Hôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
A Study on the Safety and Immune Response of a Booster Dose of Investigational COVID-19 mRNA Vaccines in Healthy Adults
Condition: SARS-CoV-2 Interventions: Biological: CV0701 Bivalent High dose; Biological: CV0701 Bivalent Medium dose; Biological: CV0701 Bivalent Low dose; Biological: CV0601 Monovalent High dose; Biological: Control vaccine Sponsors: GlaxoSmithKline; CureVac Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
Condition: SARS-CoV-2 Interventions: Drug: Upamostat; Drug: Placebo (PO) Sponsors: Henry M. Jackson Foundation for the Advancement of Military Medicine; Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies; FHI Clinical, Inc.; RedHill Biopharma Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 20, 2023 Category: Research Source Type: clinical trials
